IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

This study is comparing different treatments for relapsed or refractory acute myeloid leukemia (AML) — a type of blood cancer that has either stopped responding to treatment or come back after treatment. It is a randomized trial, meaning participants are assigned to different treatment groups to compare results. **You may be eligible if...** - You are 18 or older - You have been diagnosed with AML that is either not responding to initial treatment (primary refractory) or has come back early after treatment (early relapse) - You have signed informed consent **You may NOT be eligible if...** - Your AML relapsed late (long after treatment ended) - Your AML has spread only outside the bone marrow - Your cancer has only relapsed based on lab markers without full bone marrow relapse - You have acute promyelocytic leukemia (a specific AML subtype treated differently) - You have previously failed or stopped responding to venetoclax therapy - You have had a bone marrow or stem cell transplant in the past - You are pregnant or breastfeeding - Your general health is severely limited (ECOG score 3 or above) - You have uncontrolled infection, serious heart problems, or severe kidney disease Talk to your doctor to see if this trial is right for you.